Pfizer’s yearslong cost-cutting effort is continuing apace, and it disclosed a $4.3 billion write-down tied to a Phase 3 trial miss for sigvotatug vedotin.
Pfizer’s yearslong cost-cutting effort is continuing apace, with $2.5 billion in additional reductions planned across the entire company.
The announcement Tuesday balloons the total austerity …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pfizer will reduce its costs by $2.5 billion in another round of cutbacks which will kick in next year and run through 2029. |…
Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another…
GENEVA: Pfizer on Tuesday reported better-than-expected second-quarter results, boosted by strong demand for blood thinner…
Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical…
The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his planned…
Pfizer's sigvotatug vedotin fails Phase 3 lung cancer trial, the third Seagen-acquired ADC to disappoint in roughly a year.
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
